AstraZeneca Admits Potential Risk of TTS with Covishield Vaccine: Legal Battle Ensues

AstraZeneca, the manufacturer of the Covishield vaccine for Covid-19, has made a crucial admission in court documents regarding the vaccine’s potential to induce Thrombosis with Thrombocytopenia Syndrome (TTS), prompting a legal showdown.

Back in 2020 during the Covid-19 crisis, AstraZeneca collaborated with the University of Oxford to develop the AZD1222 vaccine, which in India was produced under the brand Covishield by the Serum Institute of India located in Pune.

TTS is a medical condition characterized by blood clot formation alongside low blood platelet count, presenting rare but severe risks to individuals. The World Health Organization has also flagged TTS as an adverse event following immunization with certain Covid-19 vaccines.

The UK pharmaceutical firm is facing a class action lawsuit over claims that its vaccine resulted in fatalities and severe injuries in some cases, as reported by The Telegraph. The legal battle has escalated with the first case filed by Jamie Scott and his wife Kate over the alleged effects of the AstraZeneca vaccine.

The High Court in the UK has seen a total of 51 cases filed by affected individuals and families seeking compensation, amounting to a staggering UK pound 100 million, as the legal dispute unfolds.